Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GLULP1, or glutamate-ammonia ligase (glutamine synthetase) pseudogene 1, is a processed pseudogene derived from the active GLUL gene, which encodes glutamine synthetase. Unlike GLUL, which catalyzes the conversion of glutamate and ammonia to glutamine, GLULP1 is non-coding due to accumulated mutations and is not translated into a functional enzyme. Some pseudogenes have regulatory functions at the RNA level or can modulate gene expression, but GLULP1, specifically, is currently only annotated as a pseudogene with no described protein product or biological activity. Its sequence is located on chromosome 5q33, and it may be transcribed as a non-coding RNA, but direct biological functions, disease associations, or clinical relevance are not established at present.
There are no mechanisms of drug action for this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate-ammonia ligase (glutamine synthetase) pseudogene 1 (GLULP1).